Ana Paula Garcia Cardoso
@anacardosomd
Followers
90
Following
415
Media
1
Statuses
47
“Young enough to change, old enough to know better.”
Sao Paulo, Brazil
Joined December 2018
What a privilege to visit City of Hope with @DrSumantaPal, including a car ride full of science talk and laughs 🚗💡 Even more special to reunite with my former resident Miguel Zugman, now shining here as a research fellow. Truly inspiring! 🇧🇷✨ #Oncology #Collaboration
0
5
18
#ProstateCancer variants ✨Germline HOXB3 X285K variant: ⏩️risk factor in men of African ancestry ⏩️better response to ARPI @albertotm82 @clovis_fraga @OncoAlert @psalustiano @DrMourato @MSdoNascimento @Lfsala
@anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero
Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant https://t.co/HlRJ6OpJo1 A recent discovery identified the germline HOXB13 X285K variant as a #ProstateCancer risk factor in men of African
1
7
19
Finally had a chance to listen to the discussion EVERYONE in the GU community is talking about via @ASCO Virtual Meeting. One of the most thoughtful & eloquent discussions I have ever seen by @jackiebrown_MD @WinshipAtEmory, summarizing excellent presentations from @MichvdHeijden
10
27
107
Presented at #ASCO25 Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive #ProstateCancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes https://t.co/a3ysjvNUo0 The
0
16
32
BREAKING from @NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.
6
393
1K
Great talk on how to best combine both biomarker (digital pathology and decipher) and stratify prostate cancer patients
Combining genomic classifier and digital pathology #ArtificialIntelligence in #ProstateCancer risk stratification. @DrSpratticus @caseccc joins @zklaassen_md @GACancerCenter discuss a study of nearly 10,000 #ProstateCancer patients comparing the 22-gene Decipher® genomic
0
0
0
We have many unanswered questions in prostate cancer and is crucial to discuss with specialist 🩵
What a great start of #OncologyHereAndNow
@OncoAlert Podcast @Silke_Gillessen & @AOmlin sharing how #APCCC started and continue to evolve in #ProstateCancer setting @wroclawski_uro @WbusatoJr @albertotm82 @clovis_fraga @psalustiano @DrMourato @MSdoNascimento @Lfsala
0
1
2
Supports the preferential indication of another non-hormonal therapeutic line for patients who progress despite intensified hormonal blockade, regardless of mHSPC or mCRPC.
Latest from #STAMPEDE - intensified AR targeting drives increased prevalence of AR mutations at progression compared to monotherapy patient samples https://t.co/STmq6om1bn
@MRCCTU @ICR_London @AttardLab
0
0
3
Great job!! #GU25
0
0
2
Now it’s time for the giant @MattGalsky at #GU25 @asco. There’s a clear additive effect of durvalumab over the benefit of neoadjuvant GEMCIS in MIB regardless if pCR was achieved or not. NIAGARA approach is becoming the standard of care….for a while…. Waiting for new ADCs + IO
0
10
22
Extended follow up for Enfortumab/pembro in 1st line advanced UC (m 26mnths). PFS and OS HRs 0.48 & 0.51 respectively. Median duration of response is 2 yrs for the 68% who responded. The 30% with CR have75% & 95% 2 year PFS and OS respectively. Overall G3+ AEs 56 vs 57 % #GU25
5
80
204
Excited & honored to be an @ASCO #GU25 Featured Voice! Grateful for the opportunity to share insights alongside such esteemed colleagues @MikeSerzanMD @drenriquegrande @ReginaBarCar @DRBakaloudiMD @bavilima @ReneeSaliby @yekeduz_emre Looking forward to meaningful discussions!
Announcing the ASCO Genitourinary Cancers Symposium Featured Voices! Follow along for a range of expert insights and join the conversation using the official hashtag: #GU25 Not yet registered? There’s still time to join us in person or online: https://t.co/Xlp99Ljp7O
4
14
45
‼️Lu-PSMA in the neadjuvant setting: could it improve outcomes through direct action on the cells and its potential to induce immune response? No other therapy has been effective for neoadjuvant tretament of PCa so far @anacardosomd @drdanielvargas @FabioSchutz @sandrocavallero
Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer out on @NatRevUrol High-risk localized #ProstateCancer is a formidable challenge due to its high rates of recurrence and metastasis despite curative attempts like surgery. The
0
8
16
Good point!!!
BRCA1/2 pathogenic variants‼️ ➡️Awareness is key to improving testing rates in men ➡️Carriers should be screened earlier for #ProstateCancer ➡️Carriers should be treated more aggressively ➡️ #TargetTherapies
@LoebStacy @anacardosomd
0
0
1
The impact of fibroblast growth factor receptor alterations in clinical outcomes of patients with advanced urothelial carcinoma: Real-world data from #LATAM population out by our OncoAlert 🚨Faculty @nataliagandur 🇦🇷and Team This study investigated the prevalence of FGFR
0
13
22
On behalf of @urologysummit & the @OncoAlert 🚨Network, extending a warm invitation to join us for the second International Urology Cancer Summit #IUCS24 HYBRID & FREE_‼️ September 27, 2024 in Portsmouth UK 🇬🇧 & ONLINE REGISTER https://t.co/Qg4NjdJSvv A great OncoAlert
1
11
19
Positive topline results for darolutamide from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC) | via @BusinessWire
businesswire.com
The Phase III ARANOTE trial, investigating NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prost...
3
22
67
🥂🍾 Great news for muscle-invasive bladder cancer patients!!! Durvalumab demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
astrazeneca.com
1
10
35
PSCA CAR T-cell therapy for #mCRPC: Phase 1 trial results. @TDorffOnc @cityofhope joins @AndreaMiyahira @PCFnews to discuss her team's work in @NatureMedicine highlighting prostate cancer's immunosuppressive environment > https://t.co/42B0xFVInu
0
7
15
Excellent review of the changes in mHSPC landscape over past decade highlighting the importance of treatment intensification ‼️combining options with different mechanisms of action ✨ progressive improvements in OS with doublets => triplets ✨more adverse events, but manageable
0
8
12